At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 9 enrolled
Drug / intervention
[131I]-SGMIB Anti-HER2 VHH1biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients: CAM-VHH1 Study
In Brief
A Phase 1 clinical trial evaluating [131I]-SGMIB Anti-HER2 VHH1 for Healthy Volunteers and Breast Cancer. Completed, enrolled 9 participants across 1 site.
Detailed Summary
Primary purpose of the clinical study is to evaluate the safety, biodistribution and radiation dosimetry of \[131I\]-SGMIB Anti-HER2 VHH1 in healthy volunteers and patients with HER2+ breast cancer. Secondary purpose of the clinical study is to evaluate the tumor uptake of \[131I\]-SGMIB Anti-HER2 VHH1 in patients with HER2+ breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers, Breast Cancer
CountriesBelgium
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartOct 2016
Primary CompletionFeb 2018
TodayJul 2026
First PostedFeb 17, 2016
Enrollment StartOct 1, 2016
Primary CompletionFeb 5, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.4 years ago
Interventions
[131I]-SGMIB Anti-HER2 VHH1biological